세계의 전립선 비대증 치료제 시장 : 시장 규모, 점유율, 동향 분석, 기회, 예측 보고서(2019-2029년)

Benign Prostatic Hyperplasia Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Therapy ; By Therapeutic Class ; By Region

US $ 4,850 ￦ 6,721,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,750 ￦ 7,968,000

Unprintable PDF (Group License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,294,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. Excel 파일이 제공됩니다.

한글목차

세계의 전립선 비대증 치료제(Benign Prostatic Hyperplasia Treatment) 시장 규모는 2029년 74억 달러 규모에 달할 전망입니다.

세계의 전립선 비대증 치료제 시장은 세계의 BPH 유병률이 증가하고 있는 것과 BPH가 되기 쉬운 노년 인구가 증가하고 있는 것, 저침습 치료 선택지가 진보하고 있는 것에 의해 활황을 나타내고 있습니다.

주요 전략 컨설팅 및 시장 조사 회사인 BlueWeave Consulting은 최근 조사인 2022년 세계의 전립선 비대증 치료제 시장 규모를 59억 7,797만 달러 규모에 달할 전망이라 추정했습니다. 2023년부터 2029년까지 예측 기간 동안 세계의 전립선 비대증 치료제 시장 규모는 3.13%의 CAGR로 성장하여 2029년 73억 8,199만 달러 규모에 달할 것이라고 BlueWeave는 예측했습니다. 세계의 전립선 비대증 치료제 시장 주요 성장 촉진 요인은 이용 가능한 치료 옵션 일반 시민 의식 증가를 포함합니다. 또한, 요도적 전립선 절제술(TURP) 도입과 같은 기술적 진보는 시장 성장 추진에 중요 역할을 합니다. TURP는 내시경 전기 수술로 비정상적인 증식으로 인한 폐색을 완화하기 위해 전립선 일부를 절제합니다. 개인 헬스케어 지출 능력 확대와 특히 신흥 국가 헬스케어 인프라 현저한 개선은 시장 확대를 더욱 추진할 것으로 예상됩니다. 전립선 비대증과 관련 비뇨기과 질환 유병률 증가는 시장 성장 중요 촉진 요인입니다. 염증 반응 증가, 교감 신경 활동, 산화 스트레스 등의 요인은 특히 비만 환자 전립선 비대증 발병에 기여합니다. 신체 호르몬 변화는 전립선 비대와 BPH 발병과 관련이 있으며 BPH 치료제 시장을 확대하고 있습니다. 또한 미개척 신흥경제국은 헬스케어 인프라 개선, 미충족 헬스케어 요구 수요 증가, 연구개발(R&D) 노력 증가로 시장 개척 큰 기회가 됩니다. 따라서 이러한 측면이 분석 기간 동안 세계의 BPH 시장 확대를 뒷받침할 것으로 예상됩니다. 그러나 BPH 치료 절차와 관련된 높은 비용과 특정 치료 옵션과 관련된 부작용과 합병증은 전체 시장 성장을 억제할 것으로 예상됩니다.

보고서 상세 분석을 통해 세계의 전립선 비대증 치료제 시장 성장 가능성, 미래 동향 및 통계 정보를 제공합니다. 또한 시장 규모 전체 예측을 촉진하는 요인도 밝히고 있습니다. 세계의 전립선 비대증 치료제 시장 최신 기술 동향과 의사 결정자가 건전한 전략 의사 결정을 수행하는 업계 통찰을 제공할 것을 약속합니다. 또한 시장 성장 촉진 요인, 과제, 경쟁력에 대해서도 분석했습니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 전립선 비대증 치료제 시장 분석

• 업계 밸류체인 분석
• DROC 분석
  • 성장 원동력
    • 전립선 비대증 유병률의 세계적인 증가
    • 전립선 비대증이 되기 쉬운 고령화 인구 증가
    • 저침습 치료 옵션 진보
  • 억제 요인
    • 전립선 비대증 치료에 수반하는 고액 비용
    • 특정 치료 옵션과 관련된 부작용과 합병증
  • 기회
    • 새롭고 효과적인 치료 옵션 개발
    • R&D 투자 증가
  • 과제
    • 시장 관계자간 치열한 경쟁
    • 특정 지역은 고급 치료 기술 도입 지연
• 기술 진보/최근 개발
• 규제 프레임워크
• 포터의 5세력 분석

제4장 세계의 전립선 비대증 치료제 시장 주요 요약

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
    • 단제요법
    • 병용 약물 요법
  • 치료 등급별
    • 알파 블로커
    • 5-α-리덕타제억제제
    • 포스포디에스테라아제-5억제제
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양(APAC)
    • 라틴아메리카(LATAM)
    • 중동 및 아프리카(MEA)

제5장 북미 전립선 비대증 치료제 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
  • 치료 등급별
  • 국가별
    • 미국
    • 캐나다

제6장 유럽 전립선 비대증 치료제 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
  • 치료 등급별
  • 국가별
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인
    • 벨기에
    • 러시아
    • 네덜란드
    • 기타 유럽

제7장 아시아태평양 전립선 비대증 치료제 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
  • 치료 등급별
  • 국가별
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주 및 뉴질랜드
    • 인도네시아
    • 말레이시아
    • 싱가포르
    • 베트남
    • APAC 기타 국가

제8장 라틴아메리카 전립선 비대증 치료제 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
  • 치료 등급별
  • 국가별
    • 브라질
    • 멕시코
    • 아르헨티나
    • 페루
    • 중남미 기타 지역

제9장 중동 및 아프리카 전립선 비대증 치료제 시장

• 시장 규모와 예측(2019-2029년)
  • 금액별
• 시장 점유율과 예측
  • 요법별
  • 치료 등급별
  • 국가별
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 카타르
    • 쿠웨이트
    • 남아프리카
    • 나이지리아
    • 알제리
    • MEA 나머지 부분

제10장 경쟁 구도

• 주요 기업과 제품 목록
• 세계의 전립선 비대증 치료제 시장 점유율 분석(2022년)
• 경영 파라미터별 경쟁 벤치마킹
• 주요 전략 전개(합병, 인수, 파트너십 등)

제11장 세계의 전립선 비대증 치료제 시장 COVID-19 감염 영향

제12장 기업 프로필(기업 주요 요약, 재무 매트릭스, 경쟁 구도, 주요 인재, 주요 경쟁, 연락처 주소, 전략 전망, SWOT 분석)

• Astellas Pharma Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• AstraZeneca plc
• Johnson& Johnson
• Pfizer Inc.
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• Urologix, LLC
• Teleflex Incorporated
• Olympus Corporation
• Merck& Co., Inc.
• Allergan plc
• Endo International plc
• Other Prominent Players

제13장 주요 전략 권장 사항

제14장 조사 방법

NJH

영문 목차

영문목차

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Set to Touch USD 7.4 Billion by 2029.

Global benign prostatic hyperplasia (BPH) treatment market is flourishing, because of increasing prevalence of BPH across the world, growing geriatric population prone to BPH, and advancements in minimally invasive treatment options.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global benign prostatic hyperplasia (BPH) treatment market size at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global benign prostatic hyperplasia (BPH) treatment market size to grow at a steady CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include an increasing awareness among the public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The growing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis. However, high costs associated with BPH treatment procedures and adverse effects and complications associated with certain treatment options are anticipated to restrain the growth of overall market during the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Overview:

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market:

COVID-19 pandemic adversely affected global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions, such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - By Therapy:

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment holds a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Competitive Landscape:

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include: Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Benign Prostatic Hyperplasia (BPH) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Benign Prostatic Hyperplasia (BPH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing prevalence of BPH globally.
    • 3.2.1.2. Growing ageing population prone to BPH.
    • 3.2.1.3. Advancements in minimally invasive treatment options.
  • 3.2.2. Restraints
    • 3.2.2.1. High costs associated with BPH treatment procedures
    • 3.2.2.2. Adverse effects and complications associated with certain treatment options
• 3.3. Opportunities
  • 3.3.1.1. Development of novel and more effective treatment options.
  • 3.3.1.2. Increasing investment in research and development.
  • 3.3.2. Challenges
    • 3.3.2.1. Intense competition among market players.
    • 3.3.2.2. Slow adoption of advanced treatment technologies in certain regions.
• 3.4. Technology Advancements/Recent Developments
• 3.5. Regulatory Framework
• 3.6. Porter's Five Forces Analysis
  • 3.6.1. Bargaining Power of Suppliers
  • 3.6.2. Bargaining Power of Buyers
  • 3.6.3. Threat of New Entrants
  • 3.6.4. Threat of Substitutes
  • 3.6.5. Intensity of Rivalry

4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share and Forecast
  • 4.2.1. By Therapy
    • 4.2.1.1. Mono drug therapy
    • 4.2.1.2. Combination drug therapy
  • 4.2.2. By Therapeutic Class
    • 4.2.2.1. Alpha blockers
    • 4.2.2.2. 5- alpha-reductase inhibitors
    • 4.2.2.3. Phosphodiesterase-5 inhibitors
    • 4.2.2.4. Others
  • 4.2.3. By Region
    • 4.2.3.1. North America
    • 4.2.3.2. Europe
    • 4.2.3.3. Asia Pacific (APAC)
    • 4.2.3.4. Latin America (LATAM)
    • 4.2.3.5. Middle East and Africa (MEA)

5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy
  • 5.2.2. By Therapeutic Class
  • 5.2.3. By Country
    • 5.2.3.1. United States
    • 5.2.3.1.1. By Therapy
    • 5.2.3.1.2. By Therapeutic Class
    • 5.2.3.2. Canada
    • 5.2.3.2.1. By Therapy
    • 5.2.3.2.2. By Therapeutic Class

6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Therapeutic Class
  • 6.2.3. By Country
    • 6.2.3.1. Germany
    • 6.2.3.1.1. By Therapy
    • 6.2.3.1.2. By Therapeutic Class
    • 6.2.3.2. United Kingdom
    • 6.2.3.2.1. By Therapy
    • 6.2.3.2.2. By Therapeutic Class
    • 6.2.3.3. Italy
    • 6.2.3.3.1. By Therapy
    • 6.2.3.3.2. By Therapeutic Class
    • 6.2.3.4. France
    • 6.2.3.4.1. By Therapy
    • 6.2.3.4.2. By Therapeutic Class
    • 6.2.3.5. Spain
    • 6.2.3.5.1. By Therapy
    • 6.2.3.5.2. By Therapeutic Class
    • 6.2.3.6. Belgium
    • 6.2.3.6.1. By Therapy
    • 6.2.3.6.2. By Therapeutic Class
    • 6.2.3.7. Russia
    • 6.2.3.7.1. By Therapy
    • 6.2.3.7.2. By Therapeutic Class
    • 6.2.3.8. The Netherlands
    • 6.2.3.8.1. By Therapy
    • 6.2.3.8.2. By Therapeutic Class
    • 6.2.3.9. Rest of Europe
    • 6.2.3.9.1. By Therapy
    • 6.2.3.9.2. By Therapeutic Class

7. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Therapeutic Class
  • 7.2.3. By Country
    • 7.2.3.1. China
    • 7.2.3.1.1. By Therapy
    • 7.2.3.1.2. By Therapeutic Class
    • 7.2.3.2. India
    • 7.2.3.2.1. By Therapy
    • 7.2.3.2.2. By Therapeutic Class
    • 7.2.3.3. Japan
    • 7.2.3.3.1. By Therapy
    • 7.2.3.3.2. By Therapeutic Class
    • 7.2.3.4. South Korea
    • 7.2.3.4.1. By Therapy
    • 7.2.3.4.2. By Therapeutic Class
    • 7.2.3.5. Australia & New Zealand
    • 7.2.3.5.1. By Therapy
    • 7.2.3.5.2. By Therapeutic Class
    • 7.2.3.6. Indonesia
    • 7.2.3.6.1. By Therapy
    • 7.2.3.6.2. By Therapeutic Class
    • 7.2.3.7. Malaysia
    • 7.2.3.7.1. By Therapy
    • 7.2.3.7.2. By Therapeutic Class
    • 7.2.3.8. Singapore
    • 7.2.3.8.1. By Therapy
    • 7.2.3.8.2. By Therapeutic Class
    • 7.2.3.9. Vietnam
    • 7.2.3.9.1. By Therapy
    • 7.2.3.9.2. By Therapeutic Class
    • 7.2.3.10. Rest of APAC
    • 7.2.3.10.1. By Therapy
    • 7.2.3.10.2. By Therapeutic Class

8. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Therapeutic Class
  • 8.2.3. By Country
    • 8.2.3.1. Brazil
    • 8.2.3.1.1. By Therapy
    • 8.2.3.1.2. By Therapeutic Class
    • 8.2.3.2. Mexico
    • 8.2.3.2.1. By Therapy
    • 8.2.3.2.2. By Therapeutic Class
    • 8.2.3.3. Argentina
    • 8.2.3.3.1. By Therapy
    • 8.2.3.3.2. By Therapeutic Class
    • 8.2.3.4. Peru
    • 8.2.3.4.1. By Therapy
    • 8.2.3.4.2. By Therapeutic Class
    • 8.2.3.5. Rest of LATAM
    • 8.2.3.5.1. By Therapy
    • 8.2.3.5.2. By Therapeutic Class

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Therapeutic Class
  • 9.2.3. By Country
    • 9.2.3.1. Saudi Arabia
    • 9.2.3.1.1. By Therapy
    • 9.2.3.1.2. By Therapeutic Class
    • 9.2.3.2. UAE
    • 9.2.3.2.1. By Therapy
    • 9.2.3.2.2. By Therapeutic Class
    • 9.2.3.3. Qatar
    • 9.2.3.3.1. By Therapy
    • 9.2.3.3.2. By Therapeutic Class
    • 9.2.3.4. Kuwait
    • 9.2.3.4.1. By Therapy
    • 9.2.3.4.2. By Therapeutic Class
    • 9.2.3.5. South Africa
    • 9.2.3.5.1. By Therapy
    • 9.2.3.5.2. By Therapeutic Class
    • 9.2.3.6. Nigeria
    • 9.2.3.6.1. By Therapy
    • 9.2.3.6.2. By Therapeutic Class
    • 9.2.3.7. Algeria
    • 9.2.3.7.1. By Therapy
    • 9.2.3.7.2. By Therapeutic Class
    • 9.2.3.8. Rest of MEA
    • 9.2.3.8.1. By Therapy
    • 9.2.3.8.2. By Therapeutic Class

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Astellas Pharma Inc.
• 12.2. Eli Lilly and Company
• 12.3. GlaxoSmithKline plc
• 12.4. AstraZeneca plc
• 12.5. Johnson & Johnson
• 12.6. Pfizer Inc.
• 12.7. Abbott Laboratories
• 12.8. Boston Scientific Corporation
• 12.9. Medtronic plc
• 12.10. Urologix, LLC
• 12.11. Teleflex Incorporated
• 12.12. Olympus Corporation
• 12.13. Merck & Co., Inc.
• 12.14. Allergan plc
• 12.15. Endo International plc
• 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations

관련자료